Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off

Cytokinetics just cracked non-obstructive HCM wide open — Myqorzo hits both primary endpoints in ACACIA-HCM, and it's a market Camzyos can't touch. Meanwhile, Pfizer's two-point-three-billion-dollar Trillium bet is officially a total write-off.

Madrigal extends its MASH empire with a billion-dollar Arrowhead deal, and a Supreme Court stay on mifepristone just made the durability of every FDA approval a live legal question.

Welcome to The Pharma Closeout for Tuesday, May fifth, twenty-twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Packed day. Let's get into it.

Cytokinetics reported positive topline results this morning from ACACIA-HCM, the pivotal Phase 3 trial of aficamten — marketed as Myqorzo — in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The trial met both dual primary endpoints at Week 36. The KCCQ Clinical Summary Score demonstrated a statistically significant improvement over placebo with a meaningful clinical separation between groups. Peak VO2 showed a statistically significant improvement versus placebo with a robust p-value.

The pVO2 delta is modest in absolute terms, but look at the washout behavior. KCCQ tracked consistently through the treatment period, then snapped back to placebo levels once the drug was removed. That's clean pharmacologic signal — you're measuring aficamten, not drift or placebo response.

Strategically, this is the play. Myqorzo is already approved for obstructive HCM. Non-obstructive HCM is the larger patient population, and Bristol Myers Squibb's Camzyos has no data here. BioPharma Dive described this as opening a multibillion-dollar market opportunity.

I'd temper the commercial timeline slightly. A supplemental NDA still needs filing and review, and the agency may want longer-duration safety data in this specific population. The competitive moat is real — but the label is probably a 2027 event.

Fair — though the market is already pricing the strategic separation, not the label date. And the secondary endpoints reinforce the case.

They do. Statistically significant improvements with p-values under 0.001 across multiple measures of symptom burden and physical function. One positive co-primary might get you a conversation with the agency. Two co-primaries plus consistent secondaries gives you a label.

If Cytokinetics files on this data, they'd own exclusive positioning in non-obstructive HCM — a population currently managed symptomatically with nothing targeting the underlying disease. The commercial separation from Camzyos stops being about market share and becomes structural.

And that reshapes the acquisition math. Cytokinetics with a single-indication cardiac myosin inhibitor is one asset profile. Cytokinetics covering both obstructive and non-obstructive HCM is a cardiovascular platform — and it prices accordingly.

Shifting to the deal side, and we start with Pfizer where the Trillium story finally has a period at the end of the sentence. The company scrapped the second and final clinical-stage CD47 blocker from the Trillium Therapeutics acquisition — that's a complete write-off of a two-point-three-billion-dollar deal. Let's bring in Marcus Webb on this one.

And here's the contrast. Pfizer also beat Q1 earnings and revenue estimates today — stock up 2.2 percent — and reaffirmed 2026 guidance. But the real headline from the call was CEO Albert Bourla explicitly ruling out mega-mergers. Reuters reported that Q1 biotech M&A activity reached a significant valuation milestone. Everyone else is going big. Bourla is saying bolt-ons only.

Which tells you Pfizer believes it can fill the patent cliff gap without writing another multibillion-dollar check that ends up like Trillium. Whether that's discipline or denial depends entirely on what the bolt-on pipeline delivers over the next 18 months.

Staying with deals — Madrigal extended its MASH franchise with an exclusive global license for Arrowhead's ARO-PNPLA3, a clinical-stage siRNA targeting the PNPLA3 gene. Deal is worth up to one billion dollars in milestone payments. And per Endpoints News, this is an asset J&J previously passed on.

PNPLA3 mutations are disproportionately prevalent in Hispanic patients with MASH — so think of this as a precision layer on top of Rezdiffra's broader base. Madrigal picking up an asset a larger company declined, at a biobucks price, and plugging it into a focused MASH commercial infrastructure — that's either opportunistic genius or someone else's informed pass. The clinical data will tell us which.

Quick hits across pipeline and workforce. Axsome is projecting eight-billion-dollar peak sales for Auvelity following its recent FDA label expansion into Alzheimer's disease agitation — an indication that vastly widens the addressable patient pool beyond MDD. Viridian scored another Phase 3 win in thyroid eye disease, stacking victories against Amgen's Tepezza. And Intercept's next-gen FXR agonist failed Phase 2.

The Intercept failure is worth pausing on. That's the same FXR mechanism class they've been trying to make work in MASH for years, and it deepens the competitive gap against Madrigal's thyroid hormone receptor approach. On the same day Madrigal adds a precision asset, Intercept loses its next-generation bet. The MASH landscape is consolidating around one winner, fast.

On the workforce side: Passage Bio slashed 75 percent of its headcount after an FDA clinical hold — near-existential for a gene therapy company. BioNTech is exiting multiple manufacturing sites with more than 1,800 jobs impacted. Novartis is closing a German site, cutting 220. Gilead is laying off Arcellx employees in California post-acquisition. And on the investment side, Sanofi is putting 294 million dollars into a new AI hub in Toronto. So the theme is consistent — shed pandemic-era capacity and legacy headcount, redeploy capital toward AI, oncology, and obesity. The companies doing the cutting and the companies doing the building are often the same ones.

That restructuring pressure makes the regulatory environment even more consequential — and the biggest regulatory story today isn't a PDUFA date. It's the Supreme Court. SCOTUS granted a one-week stay Monday morning on a lower court order that had blocked mifepristone access through mail and pharmacies. Manufacturer Danco appealed within hours of that lower court ruling.

So mifepristone is available again through those channels, but the duration of that access is genuinely unclear. STAT News framed this as making drug development riskier for everyone — and that framing extends well beyond reproductive health.

Here's the plain version of what's at stake. If a court can retroactively restrict distribution of a drug FDA approved decades ago, every marketed product with a contested political profile carries a new category of risk. Pharma legal teams are watching this case because the precedent determines whether an FDA approval is genuinely durable or subject to rolling judicial revision. That's not a policy question. It's a capital allocation question for every company with a product on the market.

Also worth noting on the regulatory side, FDA signed off on Incyte's Jakafi XR — the extended-release formulation. Lifecycle management play extending franchise protection. And looking ahead this month, we've got the Leqembi subcutaneous autoinjector PDUFA on May 24th and MannKind's Afrezza in pediatric diabetes on May 29th.

The Leqembi autoinjector is the one to flag. Convenience-driven reformulation in Alzheimer's is a real commercial lever, and if that clears smoothly, it reshapes competitive positioning against IV-only options in a category where patient compliance already determines outcomes.

What to watch for the rest of this week. The mifepristone SCOTUS stay expires in seven days, so the clock is running on whether this becomes a longer-term fight or a resolved precedent. And keep an eye on Pfizer earnings call follow-through — Bourla's anti-mega-merger stance is going to get pressure-tested by analysts, and where that R&D spend increase is actually flowing will matter more than the topline beat.

And J&J quietly advanced an IBD combination therapy into pivotal testing despite failing Phase 2 — an unusual decision that suggests they saw enough subgroup signal to redesign endpoints for the pivotal. IBD combination strategies are where the field is headed, and J&J is betting it can get there even with a messy proof-of-concept. If they're right, that pivotal design becomes a template. If they're wrong, it becomes a cautionary tale about advancing on hope. Either way, it's a program that will tell us something important about IBD development in the second half.

That is your Pharma Closeout for Tuesday, May 5th. Cytokinetics staking its claim in non-obstructive HCM, Pfizer writing off Trillium while swearing off mega-deals, Madrigal building the MASH pipeline asset by asset, and the Supreme Court keeping FDA authority in a holding pattern. If this briefing saves you time, follow us on Spotify and drop a rating — it takes ten seconds and it helps others find the show. We'll be back tomorrow.

Have a good evening, everyone. See you tomorrow. ### Episode Metadata **Title:** Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off; Madrigal's $1B MASH Deal | May 05, 2026 **Description:** Myqorzo hits both endpoints in ACACIA-HCM, opening a multibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program from the $2.3B Trillium acquisition, Madrigal licenses Arrowhead's PNPLA3 siRNA for up to $1B, and the Supreme Court keeps mifepristone in play. **Tags:** Cytokinetics, Myqorzo, aficamten, hypertrophic cardiomyopathy, HCM, ACACIA-HCM, Pfizer, Trillium Therapeutics, CD47, Madrigal, Arrowhead, MASH, PNPLA3, Rezdiffra, mifepristone, Supreme Court, Auvelity, Axsome, Viridian, Tepezza, Intercept, BioNTech, Jakafi XR, Incyte, Leqembi, Sanofi, Passage Bio, Gilead, Arcellx, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #